Status:
COMPLETED
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18-69 years
Phase:
PHASE4
Brief Summary
This study will be conducted in order to determine safety and efficacy esomeprazole, lansoprazole and pantoprazole control stomach acid by measuring the stomach acid in men and women of Hispanic origi...
Eligibility Criteria
Inclusion
- Signed informed consent
- Males and females ages 18-69 who are of Hispanic origin
- Symptoms of GERD, defined as heartburn at least 2 times a week on average over the last 3 months
Exclusion
- Female patients who are pregnant or breastfeeding
- Known intolerance or lack of response to Proton Pump Inhibitors (PPIs) such as Nexium, Prevacid, or Protonix
- Current or relevant history of non-healed ulcers, stomach surgery, or esophageal surgery
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00410592
Start Date
October 1 2006
End Date
May 1 2007
Last Update
March 11 2009
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Anaheim, California, United States
2
Research Site
Orange, California, United States
3
Research Site
San Diego, California, United States
4
Research Site
Miami, Florida, United States